ASKA Pharmaceutical Holdings Co.,Ltd.
4886.T
Get informed when a big investor buys or sells
+ FollowMarket Cap$56.91B
Close$
Share Statistics
| Market cap | $56.91 Billion |
|---|---|
| Enterprise Value | $61.63 Billion |
| Dividend Yield | $60.00 (3.24%) |
| Earnings per Share | $191.1 |
| Beta | 0.45 |
| Outstanding Shares | 28,396,114 |
Return
| Return on Equity | 6.66% |
|---|---|
| Return on Assets | 4.29% |
| Return on Invested Capital | 5.63% |
Valuation & Multiples
| P/E Ratio | 12.07 |
|---|---|
| PEG | -21.11 |
| Price to Sales | 0.8 |
| Price to Book Ratio | 0.74 |
| Enterprise Value to Revenue | 0.87 |
| Enterprise Value to EBIT | 12.16 |
| Enterprise Value to Net Income | 13 |
| Total Debt to Enterprise | 0.19 |
| Debt to Equity | 0.17 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 4, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$17.70 B
Average shareholder expectationNext Earnings Call
Expected Date
November 9, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$17.64 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About ASKA Pharmaceutical Holdings Co.,Ltd.
1,611 employees
CEO: Takashi Yamaguchi ASKA Pharmaceutical Holdings Co.,Ltd. is a Japanese enterprise that operates through its subsidiaries in three primary areas: pharmaceuticals, animal healthcare, and hormone testing services. The company's pharmaceutical division is dedi...